- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05517226
Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment
A Phase I, Parallel-group, Multi-center, Open-label, Investigation of the Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Injection of Cotadutide in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will consist of four cohorts (Cohort 1, Cohort 2, Cohort 3, and Cohort 4).
Participants will be assigned to each of the cohorts as per Child-Pugh classification:
- Cohort 1: Mild hepatic impairment (Child-Pugh A), cotadutide 50 μg
- Cohort 2: Moderate hepatic impairment (Child-Pugh B), cotadutide 50 μg
- Cohort 3: Severe hepatic impairment (Child-Pugh C), cotadutide 50 μg
- Cohort 4: Normal hepatic function, cotadutide 50 μg
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Hialeah, Florida, United States, 33014
- Research Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Research Site
-
San Antonio, Texas, United States, 78215
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must be ≥ 18 to ≤ 85 years of age at the time of signing the Informed Consent Form (ICF).
- Body mass index ≥ 18 kg/m2 to < 40 kg/m2.
- Female participants of childbearing potential must use at least one highly effective form of birth control.
- Capable of giving signed informed consent.
Participants with hepatic impairment only
- Diagnosis of chronic (≥ 6 months) and stable hepatic impairment (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status within 30 days prior to study Screening).
Exclusion Criteria:
All participants
- History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to cotadutide.
Any clinically important abnormalities in rhythm, conduction or morphology of the 12-lead resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QT interval corrected for heart rate using Fridericia's formula (QTcF), including abnormal ST-T-wave morphology, or left ventricular hypertrophy
- Prolonged QTcF > 470 ms or family history of long QT syndrome.
- PR (PQ) interval shortening < 120 ms.
- PR (PQ) interval prolongation (> 220 ms) intermittent or permanent second or third degree atrioventricular (AV) block, or AV dissociation.
- Persistent or intermittent complete bundle branch block, or intraventricular conduction delay with QRS > 119 ms.
- Any evidence of additional severe or uncontrolled systemic disease or laboratory finding that makes it unsafe for the participant to participate in the study.
- Impaired renal function, defined as estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m2 at Screening.
- Any positive result on Screening for serum hepatitis B surface antigen, anti-Core HBV antibody, hepatitis C antibody, or human immunodeficiency virus (HIV).
- Any sign and confirmation of coronavirus disease 2019 (COVID19) infection:
- Participants with concurrent or previous use of a glucagon-like peptide-1 (GLP1) receptor agonist.
- Use of prohibited prescribed or nonprescribed medication during the 2 weeks prior to the first administration of Investigational Medicinal Product (IMP) or longer if the medication has a long half-life.
- History of neoplastic disease within 5 years prior to Screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer.
- Presence of hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.
Participants with hepatic impairment only
- Severe portal hypertension or surgical porto-systemic shunts.
- Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
- Clinically relevant hepatic encephalopathy.
- Severe ascites defined as ascites requiring paracentesis and albumin at 4-week intervals or less.
- Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the 28-day Screening period.
- Post liver transplantation.
- Platelet count < 50 × 109/L and/or neutrophil count < 1.2 × 109/L and/or hemoglobin < 8.5 g/dL or INR >2.3.
Participants with normal hepatic function only
- History or presence of hepatic disease or evidence of other known forms of known chronic liver disease.
- History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Urinary albumin-to-creatinine ratio > 3 mg/μmol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Participants in each cohort will receive Dose A cotadutide subcutaneously.
|
Participants will receive cotadutide subcutaneously.
|
Experimental: Cohort 2
Participants in each cohort will receive Dose A cotadutide subcutaneously.
|
Participants will receive cotadutide subcutaneously.
|
Experimental: Cohort 3
Participants in each cohort will receive Dose A cotadutide subcutaneously.
|
Participants will receive cotadutide subcutaneously.
|
Experimental: Cohort 4
Participants in each cohort will receive Dose A cotadutide subcutaneously.
|
Participants will receive cotadutide subcutaneously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma (peak) drug concentration [Cmax]
Time Frame: Day 1 to Day 3
|
The Cmax of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Area under plasma concentration time curve from zero to infinity (AUCinf)
Time Frame: Day 1 to Day 3
|
The AUCinf of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)
Time Frame: Day 1 to Day 3
|
The AUClast of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Time Frame: Day 1 to Day 3
|
The tmax of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Terminal half-life (t½λz)
Time Frame: Day 1 to Day 3
|
The t½λz of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Apparent total body clearance (CL/F)
Time Frame: Day 1 to Day 3
|
The CL/F of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Time Frame: Day 1 to Day 3
|
The Vz/F of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed.
|
Day 1 to Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Adverse Events (AEs)
Time Frame: From time of first dose to the final follow-up visit (Day 29)
|
The safety, and tolerability of a single dose of cotadutide in participants with hepatic impairment will be assessed.
|
From time of first dose to the final follow-up visit (Day 29)
|
Incidence of ADAs (anti-drug antibodies)
Time Frame: From time of first dose to the final follow-up visit (Day 29)
|
The safety, and tolerability of a single dose of cotadutide in participants with hepatic impairment will be assessed.
|
From time of first dose to the final follow-up visit (Day 29)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D5671C00008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Impairment
-
PfizerRecruitingHealthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
-
GlycoMimetics IncorporatedCompletedModerate Hepatic Impairment | Normal Hepatic FunctionUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedSevere Hepatic Impairment | Normal Hepatic FunctionBulgaria
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
-
EQRx International, Inc.CompletedSevere Hepatic ImpairmentUnited States
-
PfizerCompleted
-
TakedaCompletedSevere Hepatic ImpairmentUnited States
-
Bausch Health Americas, Inc.TerminatedSevere Hepatic ImpairmentUnited States
-
KBP BiosciencesCovanceCompletedHealthy | Moderate Hepatic ImpairmentUnited States
Clinical Trials on Cotadutide
-
AstraZenecaCompletedChronic Kidney Diseases | Type 2 Diabetes MellitusSpain, United Kingdom, New Zealand, Australia, Canada, Poland, Germany, Japan
-
AstraZenecaCompleted
-
AstraZenecaMedImmune LLCCompleted
-
MedImmune LLCCompleted
-
MedImmune LLCCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaActive, not recruitingNon-cirrhotic Non-alcoholic Steatohepatitis With FibrosisUnited States, Austria, Italy, Thailand, Germany, Korea, Republic of, Japan, Malaysia, New Zealand, Spain, Taiwan, Turkey, Australia, Israel, Argentina, Canada, Greece, South Africa, United Kingdom, France
-
AstraZenecaQuotient SciencesCompletedChronic Kidney Disease | Type 2 Diabetes Mellitus (T2DM) | Non-alcoholic SteatohepatitisUnited Kingdom
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
AstraZenecaTerminatedNon-alcoholic SteatohepatitisGermany